Genome-wide rationally-designed mutations leading to enhanced lysine production in E. coli

US11078458B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11078458-B2
Application numberUS-202117159137-A
CountryUS
Kind codeB2
Filing dateJan 26, 2021
Priority dateJun 21, 2019
Publication dateAug 3, 2021
Grant dateAug 3, 2021

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present disclosure relates to various different types of variants in E. coli coding and noncoding regions leading to enhanced lysine production for, e.g., supplements and nutraceuticals.

First claim

Opening claim text (preview).

We claim: 1. An engineered E. coli cell comprising the following variant sequences: a promoter sequence having the nucleic acid SEQ ID NO: 2 driving transcription of a dapA gene, and further comprising one of the following proteins expression of which is not driven by a promoter sequence having a nucleic acid of SEQ ID NO: 2: a mfdY5 protein having the amino acid sequence of SEQ ID NO: 21, a nupXR5 protein having the amino acid sequence of SEQ ID NO: 22, a pck protein having the amino acid sequence of SEQ ID NO: 23, a rlmL protein having the amino acid sequence of SEQ ID NO: 26, a wzxB protein having the amino acid sequence of SEQ ID NO: 27, a ytfP protein having the amino acid sequence of SEQ ID NO: 33, a marA protein having the amino acid sequence of SEQ ID NO: 34, a marA protein having the amino acid sequence of SEQ ID NO: 35, a metL protein having the amino acid sequence of SEQ ID NO: 36, a metL protein having the amino acid sequence of SEQ ID NO: 37, a pck protein having the amino acid sequence of SEQ ID NO: 38. 2. The engineered E. coli cell of claim 1 comprising the promoter sequence having the nucleic acid SEQ ID NO: 2 driving transcription of the dapA gene and further comprising the mfdY5 protein having the amino acid sequence of SEQ ID NO: 21. 3. The engineered E. coli cell of claim 1 comprising the promoter sequence having the nucleic acid SEQ ID NO: 2 driving transcription of the dapA gene and further comprising the nupXR5 protein having the amino acid sequence of SEQ ID NO: 22. 4. The engineered E. coli cell of claim 1 comprising the promoter sequence having the nucleic acid SEQ ID NO: 2 driving transcription of the dapA gene and further comprising the pck protein having the amino acid sequence of SEQ ID NO: 23. 5. The engineered E. coli cell of claim 1 comprising the promoter sequence having the nucleic acid SEQ ID NO: 2 driving transcription of the dapA gene and further comprising the rlmL protein having the amino acid sequence of SEQ ID NO: 26. 6. The engineered E. coli cell of claim 1 comprising the promoter sequence having the nucleic acid SEQ ID NO: 2 driving transcription of the dapA gene and further comprising the wzxB protein having the amino acid sequence of SEQ ID NO: 27. 7. The engineered E. coli cell of claim 1 comprising the promoter sequence having the nucleic acid SEQ ID NO: 2 driving transcription of the dapA gene and further comprising the ytfP protein having the amino acid sequence of SEQ ID NO: 33. 8. The engineered E. coli cell of claim 1 comprising the promoter sequence having the nucleic acid SEQ ID NO: 2 driving transcription of the dapA gene and further comprising the marA protein having the amino acid sequence of SEQ ID NO: 34. 9. The engineered E. coli cell of claim 1 comprising the promoter sequence having the nucleic acid SEQ ID NO: 2 driving transcription of the dapA gene and further comprising the marA protein having the amino acid sequence of SEQ ID NO: 35. 10. The engineered E. coli cell of claim 1 comprising the promoter sequence having the nucleic acid SEQ ID NO: 2 driving transcription of the dapA gene and further comprising the metL protein having the amino acid sequence of SEQ ID NO: 36. 11. The engineered E. coli cell of claim 1 comprising the promoter sequence having the nucleic acid SEQ ID NO: 2 driving transcription of the dapA gene and further comprising the metL protein having the amino acid sequence of SEQ ID NO: 37. 12. The engineered E. coli cell of claim 1 comprising the promoter sequence having the nucleic acid SEQ ID NO: 2 driving transcription of the dapA gene and further comprising the pck protein having the amino acid sequence of SEQ ID NO: 38. 13. An engineered E. coli cell comprising the following variant sequences: a promoter sequence having the nucleic acid SEQ ID NO: 2 driving transcription of a dapA gene, and further comprising one of the following: a promoter sequence having the nucleic acid sequence of SEQ ID NO: 24 driving expression of a phoB protein; a promoter sequence having the nucleic acid sequence of SEQ ID NO: 25 driving expression of a purM protein; a promoter sequence having the nucleic acid sequence of SEQ ID NO: 28 driving expression of a ydgl protein; a promoter sequence having the nucleic acid sequence of SEQ ID NO: 29 driving expression of a ydgE protein; a promoter sequence having the nucleic acid sequence of SEQ ID NO: 30 driving expression of a yicL protein; a promoter sequence having the nucleic acid sequence of SEQ ID NO: 31 driving of a yliE protein; a promoter sequence having the nucleic acid sequence of SEQ ID NO: 32 driving expression of a yohF protein; a promoter sequence having the nucleic acid sequence of SEQ ID NO: 39 driving expression of a setB protein; a promoter sequence having the nucleic acid sequence of SEQ ID NO: 40 driving expression of a ydfO protein; a promoter sequence having the nucleic acid sequence of SEQ ID NO: 41 driving expression of a ydgD protein; or a promoter sequence having the nucleic acid sequence of SEQ ID NO: 42 driving expression of a yejD protein. 14. The engineered E. coli cell of claim 13 comprising the promoter sequence having the nucleic acid SEQ ID NO: 2 driving transcription of the dapA gene and further comprising the promoter sequence having the nucleic acid sequence of SEQ ID NO: 24 driving expression of the phoB protein. 15. The engineered E. coli cell of claim 13 comprising the promoter sequence having the nucleic acid SEQ ID NO: 2 driving transcription of the dapA gene and further comprising the promoter sequence having the nucleic acid sequence of SEQ ID NO: 25 driving expression of the purM protein. 16. The engineered E. coli cell of claim 13 comprising the promoter sequence having the nucleic acid SEQ ID NO: 2 driving transcription of the dapA gene and further comprising the promoter sequence having the nucleic acid sequence of SEQ ID NO: 28 driving expression of the ydg1 protein. 17. The engineered E. coli cell of claim 13 comprising the promoter sequence having the nucleic acid SEQ ID NO: 2 driving transcription of the dapA gene and further comprising the promoter sequence having the nucleic acid sequence of SEQ ID NO: 29 driving expression of the ydgE protein. 18. The engineered E. coli cell of claim 13 comprising the promoter sequence having the nucleic acid SEQ ID NO: 2 driving transcription of the dapA gene and further comprising the promoter sequence having the nucleic acid sequence of SEQ ID NO: 30 driving expression of the yicL protein. 19. The engineered E. coli cell of claim 13 comprising the promoter sequence having the nucleic acid SEQ ID NO: 2 driving transcription of the dapA gene and further comprising the promoter sequence having the nucleic acid sequence of SEQ ID NO: 31 driving expression of the yliE protein. 20. The engineered E. coli cell of claim 13 comprising the promoter sequence having the nucleic acid SEQ ID NO: 2 driving transcription of the dapA gene and further comprising the promoter sequence having the nucleic acid sequence of SEQ ID NO: 32 driving expression of the ydg1 protein. 21. The engineered E. coli cell of claim 13 comprising the promoter sequence having the nucleic acid SEQ ID NO: 2 driving transcription of the dapA gene and further comprising the promoter sequence having the nucleic acid sequence of SEQ ID NO: 39 driving expression of the setB protein. 22. The engineered E coli cell of claim 13 comprising the promoter sequence having the nucleic acid SEQ ID

Assignees

Inventors

Classifications

  • Lyases (4.) · CPC title

  • Cells for production · CPC title

  • C12P13/08Primary

    Lysine; Diaminopimelic acid; Threonine; Valine · CPC title

  • Cells for large scale production · CPC title

  • C12N1/20Primary

    Bacteria; Culture media therefor · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11078458B2 cover?
The present disclosure relates to various different types of variants in E. coli coding and noncoding regions leading to enhanced lysine production for, e.g., supplements and nutraceuticals.
Who is the assignee on this patent?
Inscripta Inc
What technology area does this patent fall under?
Primary CPC classification C12P13/08. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).